scholarly journals Influence of hypergastrinemia secondary to long-term proton pump inhibitor treatment on ECL cell tumorigenesis in human gastric mucosa

2020 ◽  
Vol 216 (10) ◽  
pp. 153113
Author(s):  
Atsushi Tatsuguchi ◽  
Shintaro Hoshino ◽  
Noriyuki Kawami ◽  
Katya Gudis ◽  
Tsutomu Nomura ◽  
...  
2021 ◽  
Vol 8 (1) ◽  
pp. e000563
Author(s):  
Peter Fentz Haastrup ◽  
Dorte Ejg Jarbøl ◽  
Wade Thompson ◽  
Jane Møller Hansen ◽  
Jens Søndergaard ◽  
...  

ObjectiveProton pump inhibitor (PPI) use has risen substantially, primarily driven by ongoing use over months to years. However, there is no consensus on how to define long-term PPI use. Our objectives were to review and compare definitions of long-term PPI use in existing literature and describe the rationale for each definition. Moreover, we aimed to suggest generally applicable definitions for research and clinical use.DesignThe databases PubMed and Cochrane Library were searched for publications concerning long-term use of PPIs and ClinicalTrials.gov was searched for registered studies. Two reviewers independently screened the titles, abstracts, and full texts in two series and subsequently extracted data.ResultsA total of 742 studies were identified, and 59 met the eligibility criteria. In addition, two ongoing studies were identified. The definition of long-term PPI use varied from >2 weeks to >7 years. The most common definition was ≥1 year or ≥6 months. A total of 12/61 (20%) of the studies rationalised their definition.ConclusionThe definitions of long-term PPI treatment varied substantially between studies and were seldom rationalised.In a clinical context, use of PPI for more than 8 weeks could be a reasonable definition of long-term use in patients with reflux symptoms and more than 4 weeks in patients with dyspepsia or peptic ulcer. For research purposes, 6 months could be a possible definition in pharmacoepidemiological studies, whereas studies of adverse effects may require a tailored definition depending on the necessary exposure time. We recommend to always rationalise the choice of definition.


2019 ◽  
Vol 156 (6) ◽  
pp. S-305 ◽  
Author(s):  
Atsushi Tatsuguchi ◽  
Shintaro Hoshino ◽  
Noriyuki Kawami ◽  
Katya Gudis ◽  
Katsuhiko Iwakiri

Gut ◽  
1998 ◽  
Vol 42 (2) ◽  
pp. 159-165 ◽  
Author(s):  
A El-Nujumi ◽  
C Williams ◽  
J E Ardill ◽  
K Oien ◽  
K E L McColl

Background—Both proton pump inhibitor drug treatment and Helicobacter pylori infection cause hypergastrinaemia in man.Aims—To determine whether eradicating H pylori is a means of reducing hypergastrinaemia during subsequent proton pump inhibitor treatment.Methods—Patients with H pylori were randomised to treatment with either anti-H pylori or symptomatic treatment. One month later, all received four weeks treatment with omeprazole 40 mg/day for one month followed by 20 mg/day for six months. Serum gastrin concentrations were measured before and following each treatment.Results—In the patients randomised to anti-H pylori treatment, eradication of the infection lowered median fasting gastrin by 48% and meal stimulated gastrin by 46%. When gastrin concentrations one month following anti-H pylori/symptomatic treatment were used as baseline, omeprazole treatment produced a similar percentage increase in serum gastrin in the H pylori infected and H pylorieradicated patients. Consequently, in the patients in which H pylori was not eradicated, median fasting gastrin concentration was 38 ng/l (range 26–86) at initial presentation and increased to 64 ng/l (range 29–271) after seven months omeprazole, representing a median increase of 68% (p<0.005). In contrast, in the patients randomised to H pylori eradication, median fasting gastrin at initial presentation was 54 ng/l (range 17–226) and was unchanged after seven months omeprazole at 38 ng/l (range 17–95).Conclusion—Eradicating H pylori is a means of reducing the rise in gastrin during subsequent long term omeprazole treatment. In view of the potential deleterious effects of hypergastrinaemia it may be appropriate to render patients H pylori negative prior to commencing long term proton pump inhibitor treatment.


Digestion ◽  
2013 ◽  
Vol 87 (2) ◽  
pp. 85-90 ◽  
Author(s):  
Alike W. van der Velden ◽  
Niek J. de Wit ◽  
A. Otto Quartero ◽  
Diederick E. Grobbee ◽  
Mattijs E. Numans

2006 ◽  
Vol 63 (5) ◽  
pp. AB177
Author(s):  
Jiang Qin ◽  
Yoosun Han ◽  
Jacinto Del Mazo ◽  
Qiang Cai ◽  
Jiang Qin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document